KR20210111770A - 조작된 플라겔린-유래 조성물 및 용도 - Google Patents
조작된 플라겔린-유래 조성물 및 용도 Download PDFInfo
- Publication number
- KR20210111770A KR20210111770A KR1020217021065A KR20217021065A KR20210111770A KR 20210111770 A KR20210111770 A KR 20210111770A KR 1020217021065 A KR1020217021065 A KR 1020217021065A KR 20217021065 A KR20217021065 A KR 20217021065A KR 20210111770 A KR20210111770 A KR 20210111770A
- Authority
- KR
- South Korea
- Prior art keywords
- amino acid
- flagellin
- flagellin variant
- acid residue
- variant
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Ceased
Links
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
- C07K14/24—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Enterobacteriaceae (F), e.g. Citrobacter, Serratia, Proteus, Providencia, Morganella, Yersinia
- C07K14/255—Salmonella (G)
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/164—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/02—Bacterial antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/02—Bacterial antigens
- A61K39/025—Enterobacteriales, e.g. Enterobacter
- A61K39/0275—Salmonella
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/16—Emollients or protectives, e.g. against radiation
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55516—Proteins; Peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/58—Medicinal preparations containing antigens or antibodies raising an immune response against a target which is not the antigen used for immunisation
- A61K2039/585—Medicinal preparations containing antigens or antibodies raising an immune response against a target which is not the antigen used for immunisation wherein the target is cancer
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Organic Chemistry (AREA)
- Epidemiology (AREA)
- Immunology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Gastroenterology & Hepatology (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Toxicology (AREA)
- Dermatology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862776507P | 2018-12-07 | 2018-12-07 | |
| US62/776,507 | 2018-12-07 | ||
| PCT/US2019/064954 WO2020118192A1 (en) | 2018-12-07 | 2019-12-06 | Engineered flagellin-derived compositions and uses |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| KR20210111770A true KR20210111770A (ko) | 2021-09-13 |
Family
ID=70974397
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| KR1020217021065A Ceased KR20210111770A (ko) | 2018-12-07 | 2019-12-06 | 조작된 플라겔린-유래 조성물 및 용도 |
Country Status (10)
| Country | Link |
|---|---|
| US (1) | US20220024991A1 (cg-RX-API-DMAC7.html) |
| EP (1) | EP3890769A4 (cg-RX-API-DMAC7.html) |
| JP (1) | JP2022511881A (cg-RX-API-DMAC7.html) |
| KR (1) | KR20210111770A (cg-RX-API-DMAC7.html) |
| CN (1) | CN113382742A (cg-RX-API-DMAC7.html) |
| AU (1) | AU2019392903A1 (cg-RX-API-DMAC7.html) |
| CA (1) | CA3122067A1 (cg-RX-API-DMAC7.html) |
| EA (1) | EA202191610A1 (cg-RX-API-DMAC7.html) |
| IL (1) | IL283757A (cg-RX-API-DMAC7.html) |
| WO (1) | WO2020118192A1 (cg-RX-API-DMAC7.html) |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2024085375A1 (ko) * | 2022-10-19 | 2024-04-25 | 전남대학교산학협력단 | Tlr5 활성능을 가진 플라젤린 면역증강제 유도체의 진핵세포 발현시스템을 이용한 제조 및 응용 |
| WO2024106866A1 (ko) * | 2022-11-14 | 2024-05-23 | 전남대학교 산학협력단 | 암의 치료용 면역증강 살모넬라 균주 및 이의 용도 |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR102720967B1 (ko) * | 2020-06-04 | 2024-10-23 | 가톨릭대학교 산학협력단 | 플라젤린으로부터 유도된 tlr5 작용제를 유효성분으로 포함하는 면역관문억제제의 항암 효과 증진용 약학 조성물 |
| CN119522108A (zh) * | 2022-06-01 | 2025-02-25 | 弗莱格生物公司 | Rna佐剂、其方法和用途 |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2121734B1 (en) * | 2007-02-09 | 2013-05-08 | Industry Foundation of Chonam National University | Modified flagellin improved toll-like receptor 5 stimulating activity |
| US9376495B2 (en) * | 2011-05-21 | 2016-06-28 | Macrogenics, Inc. | Deimmunized serum-binding domains and their use in extending serum half-life |
| CA2903252C (en) * | 2013-03-14 | 2023-01-17 | Research Corporation Technologies, Inc. | Ribotoxin molecules derived from sarcin and other related fungal ribotoxins |
| EP3174893B1 (en) * | 2014-07-30 | 2020-05-06 | Genome Protection, Inc. | Flagellin compositions and uses |
-
2019
- 2019-12-06 EA EA202191610A patent/EA202191610A1/ru unknown
- 2019-12-06 EP EP19892798.0A patent/EP3890769A4/en not_active Withdrawn
- 2019-12-06 CN CN201980090594.0A patent/CN113382742A/zh active Pending
- 2019-12-06 US US17/299,373 patent/US20220024991A1/en not_active Abandoned
- 2019-12-06 CA CA3122067A patent/CA3122067A1/en active Pending
- 2019-12-06 WO PCT/US2019/064954 patent/WO2020118192A1/en not_active Ceased
- 2019-12-06 JP JP2021532369A patent/JP2022511881A/ja active Pending
- 2019-12-06 AU AU2019392903A patent/AU2019392903A1/en not_active Abandoned
- 2019-12-06 KR KR1020217021065A patent/KR20210111770A/ko not_active Ceased
-
2021
- 2021-06-06 IL IL283757A patent/IL283757A/en unknown
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2024085375A1 (ko) * | 2022-10-19 | 2024-04-25 | 전남대학교산학협력단 | Tlr5 활성능을 가진 플라젤린 면역증강제 유도체의 진핵세포 발현시스템을 이용한 제조 및 응용 |
| WO2024106866A1 (ko) * | 2022-11-14 | 2024-05-23 | 전남대학교 산학협력단 | 암의 치료용 면역증강 살모넬라 균주 및 이의 용도 |
Also Published As
| Publication number | Publication date |
|---|---|
| CA3122067A1 (en) | 2020-06-11 |
| US20220024991A1 (en) | 2022-01-27 |
| IL283757A (en) | 2021-07-29 |
| EA202191610A1 (ru) | 2021-10-25 |
| CN113382742A (zh) | 2021-09-10 |
| AU2019392903A1 (en) | 2021-06-24 |
| JP2022511881A (ja) | 2022-02-01 |
| EP3890769A4 (en) | 2022-11-23 |
| EP3890769A1 (en) | 2021-10-13 |
| WO2020118192A1 (en) | 2020-06-11 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US10669316B2 (en) | Flagellin compositions and uses | |
| JP7312706B2 (ja) | 血液悪性腫瘍に対するcd47標的化治療のための投与パラメータ | |
| US20220024991A1 (en) | Engineered flagellin-derived compositions and uses | |
| JP2011149961A (ja) | 骨髄およびリンパ系細胞癌の診断および処置 | |
| JP2022522775A (ja) | Lilrb4結合抗体およびその使用方法 | |
| EP3980463A1 (en) | Anti-psgl-1 compositions and methods for modulating myeloid cell inflammatory phenotypes and uses thereof | |
| WO2016014899A1 (en) | Flagellin derivatives and uses | |
| US20250145715A1 (en) | B7-h3 targeting fusion proteins and methods of use thereof | |
| JP2025179057A (ja) | 併用療法のための患者の選択 | |
| US20080153746A1 (en) | Diagnosis and Treatment of Myeloid and Lymphoid Cell Cancers | |
| JP2022539038A (ja) | 骨髄細胞炎症性表現型を調節するための抗lrrc25組成物及び方法、ならびにその使用 | |
| WO2020163692A1 (en) | Treatment of cutaneous t cell lymphoma with targeting of cd47 pathway | |
| HK1237803A1 (en) | Flagellin compositions and uses | |
| HK1237803B (en) | Flagellin compositions and uses | |
| HK40050163B (en) | Selection of patients for combination therapy | |
| HK40050163A (en) | Selection of patients for combination therapy |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PA0105 | International application |
St.27 status event code: A-0-1-A10-A15-nap-PA0105 |
|
| PG1501 | Laying open of application |
St.27 status event code: A-1-1-Q10-Q12-nap-PG1501 |
|
| A201 | Request for examination | ||
| E13-X000 | Pre-grant limitation requested |
St.27 status event code: A-2-3-E10-E13-lim-X000 |
|
| P11-X000 | Amendment of application requested |
St.27 status event code: A-2-2-P10-P11-nap-X000 |
|
| P13-X000 | Application amended |
St.27 status event code: A-2-2-P10-P13-nap-X000 |
|
| PA0201 | Request for examination |
St.27 status event code: A-1-2-D10-D11-exm-PA0201 |
|
| D13-X000 | Search requested |
St.27 status event code: A-1-2-D10-D13-srh-X000 |
|
| E902 | Notification of reason for refusal | ||
| PE0902 | Notice of grounds for rejection |
St.27 status event code: A-1-2-D10-D21-exm-PE0902 |
|
| B15 | Application refused following examination |
Free format text: ST27 STATUS EVENT CODE: N-2-6-B10-B15-EXM-PE0601 (AS PROVIDED BY THE NATIONAL OFFICE) |
|
| PE0601 | Decision on rejection of patent |
St.27 status event code: N-2-6-B10-B15-exm-PE0601 |